<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082714</url>
  </required_header>
  <id_info>
    <org_study_id>ATTKPATRASCOVID19</org_study_id>
    <nct_id>NCT05082714</nct_id>
  </id_info>
  <brief_title>Tocilizumab Versus Baricitinib in Patients With Severe COVID-19</brief_title>
  <official_title>Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open Label, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Patras</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare safety and effectiveness of tocilizumab and&#xD;
      baricitinib in severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with COVID-19 will be assigned to one of the two arms on 1:1 ratio based on the time&#xD;
      point that PaO2/FiO2&lt;200 will be observed. Patients aged 18 years or older with PaO2/FiO2&#xD;
      &lt;200 at any time during their hospitalization will be included in the analysis irrespective&#xD;
      of values in inflammatory markers, such as CRP and ferritin. Exclusion criteria will be:&#xD;
      age&lt;18 years, pregnancy and application of mechanical ventilation prior patients' transfer to&#xD;
      our Hospital. Each patient or the patient's legally authorized representative provided&#xD;
      written or witnessed oral informed consent.&#xD;
&#xD;
      Day 1 will be considered the first day that PaO2/FiO2&lt;200 will be identified. Treatment with&#xD;
      either tocilizumab or baricitinib will start from day 1. Primary and secondary outcomes will&#xD;
      be assessed in the days described below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical ventilation or death by day 28</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to discharge over the 28-day period</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO scale at day 10</measure>
    <time_frame>day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tocilizumab plus usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baricitinib plus usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)</description>
    <arm_group_label>tocilizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1Â·73 m2</description>
    <arm_group_label>baricitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - COVID-19, PaO2/FiO2&lt;200&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years, Pregnancy, Application of mechanical ventilation prior patients'&#xD;
             transfer to our Hospital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Argyris Tzouvelekis</last_name>
    <phone>+306944840010</phone>
    <email>argyrios.tzouvelekis@fleming.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theodoros Karampitsakos</last_name>
    <phone>+306978245568</phone>
    <email>thodoriskarampitsakos@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Patras, Department of Respiratory Medicine</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Argyris Tzouvelekis</last_name>
      <phone>+306944840010</phone>
      <email>argyrios.tzouvelekis@fleming.gr</email>
    </contact>
    <contact_backup>
      <last_name>Theodoros Karampitsakos</last_name>
      <phone>+306972815658</phone>
      <email>thodoriskarampitsakos@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Argyris Tzouvelekis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodoros Karampitsakos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Patras</investigator_affiliation>
    <investigator_full_name>Argyris Tzouvelekis</investigator_full_name>
    <investigator_title>Associate Professor of Respiratory Medicine, Head Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>PaO2/FiO2</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Baricitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data will be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

